By Ptilast Updated
Aurobindo Pharma will manufacture and supply long-acting injectable HIV treatment, cabotegravir, across 133 countries through a voluntary licensing agreement. This agreement with Medicines Patent Pool and ViiV Healthcare expands access to an alternative to daily pills, offering injections every one or two months. The move aims to make the advanced treatment widely available and affordable in low and middle-income countries.